stoxline Quote Chart Rank Option Currency Glossary
Protalix BioTherapeutics, Inc. (PLX)
1.17  -0.06 (-4.88%)    05-28 15:59
Open: 1.21
High: 1.22
Volume: 495,601
Pre. Close: 1.23
Low: 1.155
Market Cap: 86(M)
Technical analysis
2024-05-28 3:54:36 PM
Short term     
Mid term     
Targets 6-month :  1.44 1-year :  1.6
Resists First :  1.24 Second :  1.37
Pivot price 1.17
Supports First :  1.03 Second :  0.85
MAs MA(5) :  1.21 MA(20) :  1.17
MA(100) :  1.36 MA(250) :  1.59
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  48.8 D(3) :  59.2
RSI RSI(14): 49.1
52-week High :  2.5 Low :  1.03
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PLX ] has closed below upper band by 48.3%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.24 - 1.24 1.24 - 1.25
Low: 1.17 - 1.17 1.17 - 1.18
Close: 1.22 - 1.23 1.23 - 1.24
Company Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Headline News

Mon, 20 May 2024
Zacks Small Cap Analysts Lower Earnings Estimates for Protalix BioTherapeutics, Inc. (NYSE:PLX) - MarketBeat

Mon, 13 May 2024
Protalix BioTherapeutics (NYSE:PLX) Announces Quarterly Earnings Results - Defense World

Sat, 11 May 2024
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript - Yahoo Finance

Fri, 10 May 2024
Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results - PR Newswire

Fri, 10 May 2024
Earnings call: Protalix BioTherapeutics Q1 2024 financial results By -

Fri, 03 May 2024
Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 - BioSpace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 73 (M)
Shares Float 65 (M)
Held by Insiders 9.4 (%)
Held by Institutions 13.4 (%)
Shares Short 6,080 (K)
Shares Short P.Month 5,680 (K)
Stock Financials
EPS 0.09
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.51
Profit Margin 16.6 %
Operating Margin -18.3 %
Return on Assets (ttm) 11.7 %
Return on Equity (ttm) 79.4 %
Qtrly Rev. Growth -27.2 %
Gross Profit (p.s.) 0.38
Sales Per Share 0.87
EBITDA (p.s.) 0.2
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio 13.11
PEG Ratio 0.6
Price to Book value 2.26
Price to Sales 1.35
Price to Cash Flow -11.45
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android